Serum clozapine levels: A review of their clinical utility

Journal of Psychopharmacology

Volumn 17, Issue 2, 2003, Pages 234-238

  Greenwood Smith, Catherine ^a   Lubman, Dan I ^a,b,c   Castle, David J ^a,c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b SUNSHINE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Clinical; Clozapine; Review; Serum levels; Therapeutic range; Toxicity

Indexed keywords

CAFFEINE; CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; CLOZAPINE; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; NICOTINE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; VALPROIC ACID; WARFARIN;

ADULT; ADVERSE DRUG REACTION; AGITATION; AGRANULOCYTOSIS; ALCOHOL ABUSE; CARDIOMYOPATHY; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; COMA; CONFUSION; CONSTIPATION; DELIRIUM; DELUSION; DIAPHORESIS; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG MONITORING; DRUG RESPONSE; ENURESIS; FEMALE; FOOD DRUG INTERACTION; GRAND MAL SEIZURE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERSALIVATION; HYPOREFLEXIA; HYPOTENSION; LETHARGY; LIVER DISEASE; MALE; MEDICAL LITERATURE; MYOCARDITIS; MYOCLONUS; NAUSEA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SYMPTOM; TACHYCARDIA; VIOLENCE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0037662808     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881103017002014     Document Type: Review

References (40)

1. Bazire S (2001) Psychotropic drug directory 2001/02. Bath Press, Bath
2. Bedry R, Deschamps L, Pehourcq F, Moore N, Pillet O, Favarel-Garrigues JC (1999) Non-fatal clozapine (Leponex) intoxication with toxicokinetic evaluation. Vet Hum Toxicol 41: 20-22
3. Bell R, McLaren A, Galanos J, Copolov D (1998) The clinical use of plasma clozapine levels. Aust NZ J Psychiatry 32: 567-574
4. Bell R, McClaren A, Copolov D (2001) How reliable are reported plasma clozapine levels? Aust NZ J Psychiatry 35: 468-473
5. Borison R L, Diamond B I, Sinha D, Gupta R P, Ajiboye P A (1988) Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 24: 260-263
6. Buur-Rasmussen B, Brosen K (1999) Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 9: 453-459
7. Carrillo J A, Herraiz A G, Ramos S I, Benitez J (1998) Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 18: 311-316
8. Coulter D M, Bate A, Meyboom R H B, Lindquist M, Edwards I R (2001) Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 322: 1207-1209
9. Devinsky O, Honigfeld G, Patin J (1991) Clozapine-related seizures. Neurology 41: 369-371
10. Dursun S M, McIntosh D, Milliken H (1999) Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry 56: 950
11. Ekblom B, Eriksson K, Lindstrom L H (1984) Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology (Berl) 83: 293-294
12. Eschweiler G W, Bartels M, Langle G, Wild B, Gaertner I, Nickola M (2002) Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine? Pharmacopsychiatry 35: 96-100
13. Ferslew K E, Hagardorn A N, Harlan G C, McCormick W F (1998) A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 31: 156-157
14. Freeman D J, Oyewumi L K (1997) Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 32: 93-100
15. Freudenreich O, Weiner R D, McEvoy J P (1997) Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry 42: 132-137
16. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer H Y (1993) Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 13: 383-390
17. Kilian J G, Kerr K, Lawrence C, Celermajer D S (1999) Myocarditis and cardiomyopathy associated with clozapine. Lancet 354: 1841-1845
18. Kronig M H, Munne R A, Szymanski S, Safferman A Z (1995) Plasma clozapine levels and therapeutic response for treatment refractory schizophrenic patients. Am J Psychiatry 152: 179-182
19. Kurz M, Hummer M, Kemmler G, Kurzthaler I, Saria A, Fleischhacker WW (1998) Long-term pharmacokinetics of clozapine. Br J Psychiatry 173: 341-344
20. Lane H Y, Chang Y C, Chang W H, Lin S K, Tseng Y T, Jann M W (1999) Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 60: 36-40
21. Le Blaye I, Donatini B, Hall M, Krupp P (1992) Acute overdosage with clozapine: a review of the available clinical experience. Pharmaceut Med 6: 169-178
22. Lieberman J A, Safferman A Z (1992) Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatry Q 63: 51-70
23. Matsuda K T, Cho M C, Lin K M, Smith M W, Young A S, Adams J A (1996) Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 32: 253-257
24. McCarthy R H (1994) Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry 27: 210-211
25. Meyer J M (2001) Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 21: 569-574
26. Miller D D, Fleming F, Holman T L, Perry P J (1994) Plasma clozapine concentrations as a predictor of clinical response: A follow-up study. J Clin Psychiatry 55(Suppl B): 117-121
27. Miller D D (1996) The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Ann Clin Psychiatry 8: 99-109
28. Mitchell P B (2000) Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol 49: 303-312
29. Olesen O V (1998) Therapeutic drug monitoring of clozapine treatment. Clin Pharmacokinet 34: 497-502
30. Olesen O V, Thomsen K, Jensen P N, Wulff C H (1995) Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross sectional study. Psychopharmacology (Berl) 117: 371-378
31. Pacia S V, Devinsky O (1994) Clozapine-related seizures: Experience with 5629 patients. Neurology 44: 2247-2249
32. Panagiotis B (1999) Grand mal seizures with liver toxicity in a case of clozapine treatment. J Neuropsychiatry Clin Neurosci 11: 117-118
33. Pantelis C, Adesanya A (2001) Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aust NZ J Psychiatry 35: 544-545
34. Perry P J, Miller D D, Arndt S V, Cadoret R J (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148: 231-235
35. Perry P J, Bever K A, Arndt S, Combs M D (1998) Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 44: 733-738
36. Potkin S G, Bera R, Gulasekaram B (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55(Suppl B): 133-136
37. Sartorius A, Hewer W, Zink M, Henn F A (2002) High-dose clozapine intoxication. J Clin Psychopharmacol 22: 91-92
38. Seeman P, Tallerico T (1999) Rapid release of antipsychotic drugs from D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156: 876-884
39. Uges D R A, Boom K, Wientjes G D, Versteege J (2000) Therapeutic drug monitoring of clozapine: an unexpected outcome. Ther Drug Monit 22: 323-324
40. Young C R, Bowers M B, Mazure C M (1998) Management of the adverse effects of clozapine. Schizophr Bull 24: 381-390